Fractyl Health Inc. (GUTS)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial
Fractyl Health NASDAQ: GUTS is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer Harith Rajagopalan said during a Canaccord discussion.
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health Q2 Earnings Call Highlights
Fractyl Health NASDAQ: GUTS said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission later in the year.
Fractyl Health Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Daniel Russell Naviter Wealth LLC | 15,280 | $13,278.32 | $10,689.89 | -$2,588.43 | -19.49% |
 Dinan Hu R Squared Ltd | 19,966 | $27,765.26 | $13,676.71 | -$14,088.55 | -50.74% |
 Rekah Franca Catalyst Funds Management Pty Ltd. | 12,725 | $5,825.49 | $8,902.41 | $3,076.92 | 52.82% |
| JS Jeffrey Sjovall Phraction Management LLC | 41,000 | $18,778 | $28,085 | $9,307 | 49.56% |
 Olga Maltseva Catalio Capital Management LP | 6.17M | $9.59M | $4.19M | -$5.4M | -56.26% |
Fractyl Health Inc. (GUTS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fractyl Health Inc. ever had a stock split?
Fractyl Health Inc. Profile
| Biotechnology Industry | Healthcare Sector | Harith Rajagopalan CEO | NASDAQ (NMS) Exchange | 35168W103 CUSIP |
| US Country | 100 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Fractyl Health, Inc. is a metabolic therapeutics company committed to developing innovative treatments for type 2 diabetes (T2D) and obesity. Originally founded as Fractyl Laboratories Inc., the company underwent a name change to Fractyl Health, Inc. on June 09, 2021. Since its incorporation in 2010, Fractyl Health has been at the forefront of addressing the underlying causes of these metabolic disorders. Its headquarters are located in Burlington, Massachusetts, signifying its strong presence in the hub of health and biotech innovation.
Products and Services
- Revita DMR System (Revita)
- Rejuva
Fractyl Health, Inc. has developed the Revita DMR System, an advanced outpatient procedural therapy primarily aimed at modifying duodenal dysfunction. This condition arises as a pathological consequence of consuming a high fat and high sugar diet, leading to the initiation of T2D and obesity in individuals. Revita represents a significant stride in durable treatment methods, focusing on the root cause rather than simply managing symptoms of these widespread metabolic disorders.
Expanding its suite of groundbreaking metabolic treatments, Fractyl Health, Inc. is also pioneering Rejuva, a novel gene therapy platform. Utilizing adeno-associated virus vectors, Rejuva targets the pancreatic islet cells to durably alter the function of metabolic hormones. This innovative approach is designed to achieve long-term remission of T2D and obesity, potentially revolutionizing the way these conditions are treated by directly addressing their metabolic underpinnings.
